One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Illumina logo
Illumina ILMN
$ 207.8 -8.28%
report update icon

Quarterly report 2026-Q3
added 10-30-2026

Illumina Financial Statements 2025-2007 | ILMN

Annual Financial Statements Illumina

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008 2007

Market Cap

25.3 B 16.4 B 33.4 B 31.7 B 55.9 B - 46.2 B 41.9 B 23.5 B 22.4 B - 27.6 B 18.1 B 6.4 B 8.75 B 4.97 B 4.47 B -

Shares

155 M 159 M 158 M 150 M 147 M - 147 M 147 M 147 M 145 M - 136 M 125 M 123 M 124 M 123 M 117 M -

Historical Prices

163 103 211 211 380 370 332 300 218 128 192 185 111 55.6 30.5 40.4 38.3 16.1

Net Income

850 M -1.22 B -1.16 B 762 M 656 M - 1 B 826 M 463 M 462 M 118 M 353 M 125 M 86.6 M 125 M 35.4 M 39.4 M -

Revenue

4.34 B 4.37 B 4.5 B 4.53 B 3.24 B - 3.54 B 3.33 B 2.4 B 2.22 B - 1.86 B 1.42 B 1.06 B 903 M - - -

Cost of Revenue

1.47 B 1.51 B 1.76 B 1.37 B 1.04 B - 1.08 B 1.03 B 926 M 671 M - 564 M 509 M 375 M 301 M 212 M 220 M -

Gross Profit

2.87 B 2.86 B 2.74 B 3.15 B 2.2 B - 2.47 B 2.3 B 1.67 B 1.55 B 388 M 1.3 B 912 M 709 M 602 M 157 M 353 M -

Operating Income

807 M -833 M -1.07 B -123 M 580 M - 985 M 883 M 606 M 613 M - 515 M 134 M 201 M 212 M 126 M 80.5 M -

Interest Expense

340 M -292 M -29 M 61 M 49 M - 52 M 57 M 37 M 43 M - 41.7 M 39.7 M 37.8 M 24.6 M 23.7 M 22.2 M -

EBITDA

1.08 B -479 M -637 M 128 M 767 M - 1.23 B 1.06 B 728 M 740 M - 627 M 232 M 268 M 254 M 150 M 97.7 M -

Operating Expenses

2.06 B 3.69 B 3.81 B 3.28 B 1.62 B - 1.43 B 1.42 B 1.08 B 936 M 388 M 783 M 778 M 510 M 390 M 328 M 273 M -

General and Administrative Expenses

1.09 B 1.09 B 1.61 B 2.09 B 941 M - 835 M 794 M 583 M 525 M - 464 M 368 M 262 M 220 M 176 M 148 M -

All numbers in USD currency

Quarterly Income Statement Illumina

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2

Shares

151 M 151 M 153 M - 153 M 157 M 159 M - 159 M 159 M 159 M - 158 M 158 M 158 M 157 M 157 M 157 M 157 M 146 M 152 M 146 M 146 M - 146 M 147 M 147 M 147 M 147 M 147 M 147 M 147 M 147 M 147 M 147 M 147 M 146 M 146 M 146 M 147 M 147 M 147 M 147 M - 145 M 144 M 144 M 144 M 141 M 131 M 128 M 128 M 125 M 124 M 124 M 124 M 123 M 123 M 123 M 127 M 122 M 123 M 127 M - 125 M 123 M

Net Income

220 M 207 M 134 M 334 M 150 M 235 M 131 M 186 M 705 M -1.99 B -126 M -176 M -754 M -234 M 3 M -139 M -3.82 B -535 M 86 M 113 M 317 M 185 M 147 M 257 M 179 M 179 M 179 M 239 M 234 M 296 M 233 M 198 M 199 M 209 M 208 M 58 M 163 M 128 M 367 M 108 M 129 M 120 M 90 M 103 M 118 M 102 M 137 M 153 M 93.5 M 46.6 M 60 M 80.7 M 31.4 M 35.9 M -22.6 M 71.9 M 29.7 M 23.4 M 26.2 M 11.7 M 20.2 M 30.6 M 24.1 M 38.4 M 35.4 M 29.8 M

Revenue

1.13 B 1.16 B 1.09 B - 1.08 B 1.06 B 1.04 B 1.1 B 1.08 B 1.11 B 1.08 B - 1.12 B 1.18 B 1.09 B 1.08 B 1.12 B 1.16 B 1.22 B - 1.11 B 1.13 B 1.09 B - 794 M 633 M 859 M 953 M 907 M 838 M 846 M 867 M 853 M 830 M 782 M 778 M 714 M 662 M 598 M 592 M 607 M 600 M 572 M - 550 M 539 M 539 M 512 M 481 M 448 M 421 M 387 M 357 M 346 M 331 M 309 M 286 M 281 M 273 M 261 M 235 M 287 M 283 M - - -

Cost of Revenue

299 M 389 M 370 M - 351 M 364 M 358 M 376 M 335 M 391 M 409 M - 435 M 444 M 432 M 411 M 398 M 395 M 408 M - 338 M 324 M 329 M - 268 M 205 M 240 M - 259 M 265 M 262 M - 256 M 255 M 244 M - 232 M 228 M 230 M - 181 M 176 M 175 M - 163 M 163 M 164 M - 147 M 147 M 142 M - 147 M 123 M 112 M - 90 M 87.6 M 91.8 M - 78.4 M 94.1 M 94.5 M - 80.2 M 65.9 M

Gross Profit

830 M 770 M 721 M - 733 M 695 M 683 M 728 M 745 M 721 M 667 M - 684 M 732 M 655 M 672 M 717 M 767 M 815 M - 770 M 802 M 764 M - 526 M 428 M 619 M 662 M 648 M 573 M 584 M 590 M 597 M 575 M 538 M 542 M 482 M 434 M 368 M 419 M 426 M 424 M 397 M 410 M 388 M 376 M 375 M 385 M 334 M 301 M 278 M 259 M 210 M 223 M 219 M 204 M 196 M 193 M 181 M 171 M 157 M 193 M 188 M 166 M 157 M 146 M

Operating Income

305 M 245 M 209 M - 227 M 214 M 164 M 175 M 741 M -1.64 B -111 M - -754 M -88 M -64 M -127 M -3.66 B -579 M 184 M - -545 M 187 M 193 M - 162 M 96 M 189 M - 308 M 205 M 204 M - 241 M 227 M 218 M - 181 M 143 M 52 M - 161 M 162 M 121 M - 141 M 152 M 176 M - 119 M 100 M 92.1 M - 45.5 M 60 M -45.1 M - 48.8 M 43 M 49.6 M - 36.8 M 66 M 69.4 M - 57.3 M 47.4 M

Interest Expense

-29 M 31 M -39 M - 9 M 107 M 32 M 27 M 4 M -332 M 18 M - 19 M 1 M 20 M -39 M -12 M 6 M 6 M - 14 M 16 M 19 M - 11 M 11 M 11 M - 11 M 15 M 15 M - 15 M 11 M 11 M - 10 M 8 M 8 M - 9 M 8 M 8 M - 12.8 M 11.2 M 11.2 M - 11 M 9.92 M 9.74 M - 9.95 M 10 M 9.75 M - 9.48 M 9.51 M 9.2 M - 8.8 M 9.42 M 7.39 M - 6.19 M 6.13 M

EBITDA

305 M 347 M 260 M - 294 M 282 M 233 M 192 M 758 M -1.53 B -52 M - -579 M -39 M -7 M -78 M -3.66 B -477 M 234 M - -480 M 269 M 234 M - 208 M 171 M 226 M - 421 M 281 M 241 M - 341 M 292 M 248 M - 262 M 195 M 78 M - 226 M 204 M 142 M - 194 M 186 M 193 M - 164 M 130 M 107 M - 82.5 M 83.7 M -33.4 M - 84.4 M 66.5 M 61.6 M - 77.1 M 92 M 82.2 M - 81.9 M 63.2 M

Operating Expenses

525 M 525 M 512 M - 506 M 481 M 519 M 553 M 4 M 2.36 B 778 M - 1.44 B 820 M 719 M 799 M 4.37 B 1.35 B 631 M - 1.32 B 615 M 571 M - 364 M 332 M 430 M 662 M 340 M 368 M 380 M 590 M 356 M 348 M 320 M 542 M 301 M 291 M 316 M 419 M 265 M 262 M 276 M 410 M 247 M 224 M 199 M 385 M 214 M 200 M 186 M 259 M 164 M 163 M 264 M 204 M 147 M 150 M 131 M 171 M 120 M 127 M 119 M 166 M 99.8 M 98.7 M

General and Administrative Expenses

281 M 273 M 272 M - 277 M 234 M 267 M 279 M 239 M 147 M 439 M - 303 M 462 M 378 M 432 M 146 M 410 M 308 M - 879 M 413 M 374 M - 192 M 177 M 274 M - 189 M 202 M 211 M - 197 M 197 M 183 M - 167 M 161 M 171 M - 139 M 148 M 150 M - 137 M 124 M 116 M - 120 M 115 M 110 M - 95.6 M 88.7 M 85.1 M - 69.8 M 68.5 M 68 M - 66 M 69.2 M 65.7 M - 55 M 53.7 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Illumina ILMN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Illumina plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Co-Diagnostics Co-Diagnostics
CODX
$ 0.27 -24.13 % $ 359 K usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 13.26 3.35 % $ 139 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 2.74 -7.74 % $ 10.9 M israelIsrael
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 50.87 0.11 % $ 11 B niderlandNiderland
Myriad Genetics Myriad Genetics
MYGN
$ 6.29 4.49 % $ 582 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.01 1.32 % $ 3.94 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 16.48 -3.91 % $ 2.11 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.75 -1.41 % $ 1.31 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 2.42 -4.9 % $ 726 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 11.67 -6.38 % $ 2.54 B usaUSA
Precipio Precipio
PRPO
$ 18.57 -5.11 % $ 29.8 M usaUSA
Personalis Personalis
PSNL
$ 15.53 -1.65 % $ 1.39 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 12.82 -10.7 % $ 540 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Guardant Health Guardant Health
GH
$ 154.56 -8.32 % $ 19.4 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 25.49 -5.84 % $ 571 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 120.47 -15.51 % $ 7.21 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Agilent Technologies Agilent Technologies
A
$ 171.62 -3.14 % $ 48.7 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 312.54 -4.19 % $ 15.5 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 100.73 -0.41 % $ 6.8 B usaUSA
Natera Natera
NTRA
$ 363.86 -6.95 % $ 49.7 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 363.12 -1.26 % $ 30.2 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 34.15 -4.49 % $ 990 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 253.91 -0.69 % $ 28.2 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 226.89 -3.44 % $ 162 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 677.93 -2.66 % $ 34.6 B schweizSchweiz
DexCom DexCom
DXCM
$ 84.0 -5.06 % $ 32.8 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 30.5 -1.74 % $ 28.9 B niderlandNiderland
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
RadNet RadNet
RDNT
$ 78.05 -2.75 % $ 5.87 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Sotera Health Company Sotera Health Company
SHC
$ 15.87 -3.2 % $ 4.51 B usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 10.6 -5.44 % $ 360 M israelIsrael
Neuronetics Neuronetics
STIM
$ 2.43 -10.17 % $ 160 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 676.84 -4.18 % $ 255 B usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 5.9 -8.28 % $ 2.12 B irlandaIrlanda